Vijaya Diagnostic Centre Limited has informed the Exchange about Investor Presentation

VIJAYADIAGNOSTICCRENovember10,2022To,ListingDepartmentNationalStockExchangeoInExchangePlaza,BandraKurlaComplex,Bandra(East),Mumbai-400051CompanyCodeNo.VIJAYADearSir/Madam,To,TheCorporateRelationsDepartmentBSELimited,PhirozieejeebhoyTowers,25thFloor,DalalStreetMumbai-400001CompanyCodeNo.543350PursuanttoRegulation30(2)ofSEBI(ListingObligationsandDisclosureRequirements)Regulations,2015,weareenclosingherewiththepresentationthatwouldbeusedintheInvestors/AnalystsearningsconferencecallscheduledtobeheldonNovember11,2022at12.00noon1ST.PleasetaketheinformatioThankingyou,recordForVijayaDiagnosticCentreLimitedAnushaKanumuruCompanySecretaryVijayaDiagnosticCentreLimited(FormerlyknownasVijayaDiagnosticCentrePvt.Ltd.),3-6-16&17,Street#19,HimayathNagar,Hyderabad-29,Telangana~b040-23420422to271~info@vijayadiagnostic.comIwww.vijayadiagnostic.comCINNo.L85195TG2002PLC039075aLimited,Sub:InvestorPresentation.mePioneersInDIagnosticMeflicare...Vijaya Diagnostic Centre LimitedQ2 & H1FY23 Earnings PresentationNovember 10, 2022Safe Harbour2Thispresentationandtheaccompanyingslides(the“Presentation”),whichhavebeenpreparedbyVijayaDiagnosticCentreLimited(the‘Company’),havebeenpreparedsolelyforinformationpurposesanddonotconstituteanyoffer,recommendationorinvitationtopurchaseorsubscribeforanysecurities,andshallnotformthebasisorbereliedoninconnectionwithanycontractorbindingcommitmentwhatsoever.NoofferingofsecuritiesoftheCompanywillbemadeexceptbymeansofastatutoryofferingdocumentcontainingdetailedinformationabouttheCompany.ThisPresentationhasbeenpreparedbytheCompanybasedoninformationanddatawhichtheCompanyconsidersreliable,buttheCompanymakesnorepresentationorwarranty,expressorimplied,whatsoever,andnorelianceshallbeplacedonthetruth,accuracy,completeness,fairnessandreasonablenessofthecontentsofthisPresentation.ThisPresentationmaynotbeallinclusiveandmaynotcontainalloftheinformationthatyoumayconsidermaterial.Anyliabilityinrespectofthecontentsof,oranyomissionfrom,thisPresentationisexpresslyexcluded.CertainmattersdiscussedinthisPresentationmaycontainstatementsregardingtheCompany’smarketopportunityandbusinessprospectsthatareindividuallyandcollectivelyforward-lookingstatements.Suchforward-lookingstatementsarenotguaranteesoffutureperformanceandaresubjecttoknownandunknownrisks,uncertaintiesandassumptionsthataredifficulttopredict.Theserisksanduncertaintiesinclude,butarenotlimitedto,theperformanceoftheIndianeconomyandoftheeconomiesofvariousinternationalmarkets,theperformanceoftheindustryinIndiaandworld-wide,competition,theCompany’sabilitytosuccessfullyimplementitsstrategy,theCompany'sfuturelevelsofgrowthandexpansion,technologicalimplementation,changesandadvancements,changesinrevenue,incomeorcashflows,theCompany'smarketpreferencesanditsexposuretomarketrisks,aswellasotherrisks.TheCompany'sactualresults,levelsofactivity,performanceorachievementscoulddiffermateriallyandadverselyfromresultsexpressedinorimpliedbythisPresentation.TheCompanyassumesnoobligationtoupdateanyforward-lookinginformationcontainedinthisPresentation.Anyforward-lookingstatementsandprojectionsmadebythirdpartiesincludedinthisPresentationarenotadoptedbytheCompanyandtheCompanyisnotresponsibleforsuchthird-partystatementsandprojections.AllMapsusedinthePresentationarenottoscale.Alldata,informationandmapsareprovided"asis"withoutwarrantyoranyrepresentationofaccuracy,timelinessorcompleteness.Q2 & H1FY23 Financial Performance42.63 Mn Tests0.85 Mn Footfalls INR 1,207.5 MnRevenue95% B2C RevenueINR 487.4 MnEBIDTA40.4%EBIDTA MarginINR 233.3 MnProfit After Tax19.3%PAT MarginOperational & Financial Highlights –Q2 FY23113 Centres(opened 13)Q2 FY23 –Performance SnapshotINR 1,172.4 Mn (97%)Non-COVIDCOVIDINR 35.0 Mn (3%)67.6%15.1%Management comment5Commenting on the Q2FY23 results performance, Ms. SupritaReddy, CEO at Vijaya Diagnostic Centre Ltd. said:“WehavedeliveredanencouragingperformanceinQ2FY23withourrevenuesincreasingby15.7%andEBITDAincreasingby22.2%onaQ-o-Qbasis.Despiteconsiderablyexpandingourcenters,ourteamshavemadededicatedeffortstodriveefficienciesleadingtoindustry-leadingEBITDAmarginsof40.4%duringthequarter.Wehaverecentlyoperationalizedoneofourlargest16,000sq.ft.state-of-the-artPunjaguttacentreinHyderabad.Alongwiththecommissioningofmajorhubsinthepastfewmonths,wehavemadehealthyprogressonexpandingourmidandsmallsizedspokesinourfocusedmarketsduringthequarter.Furthermore,variousstepstoenhancetheoveralldigitizationaspectinouroperationsareprogressingwellandweexpectthesedigitalinitiativestoconsiderableenhancetheoveralloperationalefficiencyatallourcentres.Thekeypillarsofourbusinessareourintegrateddiagnosticservices,substantialpresenceinhigh-marginB2Cbusiness,andastrongbrandsalience.ThiscoupledwithourotherinherentstrengthsshouldassisttheCompanytodeliversustainablegrowth,goingforward.”Key Financial Highlights –Q2 & H1 FY236Revenue from OperationsEBITDA & EBITDA Margin (%)(INR Mn)1,1271,0441,2072,3542,251Q2 FY22Q1 FY23Q2 FY23H1 FY22H1 FY23Shift YoY (%)7.1%-4.4%5113994871,08088645.4%38.2%40.4%45.9%39.4%Q2 FY22Q1 FY23Q2 FY23H1 FY22H1 FY23-4.7%-17.9%PAT & PAT Margin (%)27717523360740824.6%16.7%19.3%25.8%18.1%Q2 FY22Q1 FY23Q2 FY23H1 FY22H1 FY23Shift YoY (%)-15.8%-32.8%90%97%97%10%3%3%Q2 FY22Q1 FY23Q2 FY23Non CovidCovidRevenue Mix –Q2 & H1FY237(INR Mn)Radiology vs. Pathology BreakdownNon-COVID & COVID Allied Breakdown33%36%33%32%34%67%64%67%68%66%Q2 FY22Q1 FY23Q2 FY23H1FY22H1FY23RadiologyPathology82%97%18%3%H1FY22H1FY23Non CovidCovidB2C Contribution –Q2 FY23 & H1FY23 B2C95%B2B5%Non-COVID YoY (%)15.1%COVID YoY (%)-67.6%Non-COVID YoY (%)13.4%COVID YoY (%)-84.3%Q2 & H1FY23 –Key Developments8Continuedpositivemomentumwitnessedinoperationalperformance•Thecompanyregisteredgrowthonamonth-on-monthbasisonthebackofhealthytractionseeninnon-covidbusinessacrossallsegments•Astheenvironmentnormalizes,thenon-covidofferingswouldcontinuetoshifttopre-pandemiclevelsNon-COVID Test Volumes (# in Million)0.680.730.760.790.870.90Apr-22May-22Jun-22Jul-22Aug-22Sep-22Launches state-of-the-art PunjaguttaCentre•VDCLrecentlyoperationalizedits16,000sq.ft.centreatPunjagutta,Hyderabad•Thisstate-of-the-artfacilityisthefirstdiagnosticcentreinSouthIndiatohave‘Walk-inWalk-outDualsourceCT’and‘BioMatrix3T’•Additionally,thecentreisalsowellequippedwithotheradvancedradiologyequipment’slike‘PETCT’and‘GammaCamera’PunjaguttaFacilityDual source CTWide Bore 3T MRIQ2 & H1FY23 -Financial and Operational Discussions (Y-o-Y)9Financial PerformanceQ2FY23•RevenuefromOperationsincreasedby7.1%YoYtoRs.1,207Mn,Non-CovidRevenuesgrewby15.1%YoY•DuringQ2FY23,theCompanywitnessedmonth-on-monthimprovementinbusinessacrossallsegmentsthatassistedrevenueperformanceandregisteredQ-o-Qgrowthof15.7%•WellnessshareinQ2FY23wasupat12.4%asagainst6.7%inQ2FY22•RevenuecompositionfromB2Csegmentstoodat95%•EBITDAstoodatRs.487Mn.EBITDAmarginforthequarterwas40.4%•Healthynoncovidtestvolumescoupledwithoperatingleverageassistedmarginperformancedespitehighercostsonaccountofrecentlycommissionedfacilities•PATstoodatRs.233Mn.translatingintoaPATmarginof19.3%•RevenuefromOperationsdecreasedby4.4%YoYtoRs.2,251Mn,Non-CovidRevenuesgrewby13.4%YoY•WellnessshareinH1FY23wasupat11.1%asagainst5.3%inH1FY22•RevenuecompositionfromB2Csegmentcontinuedtostaystrongat95%•EBITDAstoodatRs.886Mn.EBITDAmarginforthequarterwas39.4%•PATstoodatRs.408Mn.translatingintoaPATmarginof18.1%Financial PerformanceH1FY23Key Financial Highlights10Cash flow from Operations / EBITDA (%)Cash & Cash Equivalents (INR Mn)164.0%98.7%176.7%77.7%97.2%Q2FY22Q1FY23Q2FY23H1FY22H1FY232,2862,3542,4932,2862,493Q2 FY22Q1 FY23Q2 FY23H1 FY22H1 FY23Working Capital Days1-11-9-12-11-13Q2FY22Q1FY23Q2FY23H1FY22H1FY23•CashflowfromOperationsstoodatRs.861mn.asonSept.30,2022•CashandCashEquivalentsstoodatRs.2,493mn.asonSept.30,2022•WorkingCapitalDayscontinuestoremainnegativeat-12inQ2FY23Note1:QuarterlyRevenuefiguresareannualizedKey Operational Highlights11•CompanyrecordedsteadygrowthinNo.oftestsonYoYbasisledbyNon-COVIDcustomersinH1FY23Tests Performed (# in Million)Footfalls (# in Million)2.362.232.634.554.86Q2 FY22Q1 FY23Q2 FY23H1FY22H1FY230.870.750.851.811.60Q2 FY22Q1 FY23Q2 FY23H1FY22H1FY23Revenue per Test (INR)Revenue per Footfall (INR)477469459518464Q2 FY22Q1 FY23Q2 FY23H1FY22H1FY231,2951,3951,4181,2971,407Q2 FY22Q1 FY23Q2 FY23H1FY22H1FY23Tests / Footfalls (# in Million)2.722.983.092.513.04Q2 FY22Q1 FY23Q2 FY23H1FY22H1FY23Consolidated Profit & Loss Account –Q2 & H1 FY23ParticularsQ2 FY23Q2 FY22Y-o-YQ1 FY23Q-o-QH1 FY23H1 FY22Y-o-YRevenue from operations1,207.51,127.17.1%1,043.615.7%2,251.1 2,353.9 -4.4%Cost of materials consumed166.5162.42.6%130.327.8%296.9 373.2 -20.5%Employee benefits expense197.4171.015.5%194.81.4%392.2 332.4 18.0%Other expenses356.1282.326.2%319.611.4%675.7 568.3 18.9%EBITDA487.4511.5-4.7%398.922.2%886.31,080.0-17.9%EBITDA Margin (%)40.4%45.4%-500 bps38.2%220 bps39.4%45.9%-650 bpsOther income33.031.54.7%27.719.3%60.764.4-5.7%Depreciation and amortization expense159.0124.827.5%141.812.2%300.8244.023.3%EBIT361.4418.3-13.6%284.926.9%646.3900.4-28.2%Finance costs48.739.423.8%47.72.3%96.479.421.4%Profit before Tax312.7378.9-17.5%237.231.8%549.9821.0-33.0%Tax expenses78.098.9-21.1%61.626.6%139.7207.814-32.8%Profit beforeMinority Interest234.7280.0-16.2%175.633.7%410.2613.2-33.1%Minority Interest1.42.9-50.2%1.132.7%2.56.4-61.2%Profit after Tax (PAT)233277-15.8%17533.7%408607-32.8%PAT Margin (%)19.3%24.6%-530 bps16.7%260 bps18.1%25.8%-770 bpsEPS –Basic (INR)*2.32.7-15.8%1.729.2%4.06.0-32.8%(INR Mn)12*Not annualizedCompany OverviewVijaya Diagnostic Centre Limited is the largest integrated diagnostic chain in South India with 113 state-of-the-art centresspread across 17 citiesOurVisionistoprovidereliableandaccuratediagnosticservicestoourcustomers,ataffordableprices,inacustomer-centricmanner.Westrivetoprovidethebestservicepossible.Wearecontinuallyraisingourownbarthroughthelatesttechnology,continuousimprovementandrecruitmentofhighcalibretechniciansandprofessionalMissionOurMissionistomakethepatient’smedicaljourneyfaster,moretransparentandmoreaccurate.Wearecommittedtodeliverexceptionaldiagnosticsolutionstoeverypatientandphysician14Vision200+DoctorsRadiologists, Pathologists & Microbiologists~3.6 MnFootfallsTrusted by every Age group40+Years of ExperienceExperience in delivering Quality Diagnostic Service at affordable prices~9.3 MnTestsMost preferred Diagnostic Centre113CentresState-of-the-art Facilities with Best-in-class TechnologyQualityReliable & Accurate Diagnosticsat Affordable Prices18Cities across IndiaLargest integrated player in South IndiaFootfalls & Tests for 12 months ending Mar 2022Vijaya at a GlanceOur JourneyVijaya Diagnostic Centre incorporated in HyderabadRecognized as one of the Best Imaging centres in Hyderabad by The WeekAwarded Brand of the year in diagnostic services by The CEO Magazine and Telangana Healthcare Leadership awardOne of the earliest private diagnostic service providers to be approved for COVID RT-PCR testing by ICMR*15*ICMR: Indian Council of Medical Research; NSE: National Stock Exchange, BSE: Bombay Stock ExchangeAwarded one of the Best Healthcare Brands 2022 by The Economic TimesWon the Healthcare Leadership Awards 2022Awarded Pride of India Brands Award –The Best of South Awards 2022First independent diagnostic centrein South India to offer PET CT from Wipro GE Healthcare Pvt. Ltd.Investment by Karakoram Limited and KedaaraCapital Alternative Investment Fund –KedaaraCapital AIF1Awarded Best Diagnostic Centre –India by Times Healthcare Achievers GroupSuccessfully listed on Indian Stock Exchanges (NSE & BSE)First independent diagnostic centrein Telangana to get Revolution ACT 50 slice CT from Wipro GE Healthcare Pvt. Ltd198120082012201820202022201620192021At the Forefront of Introducing New Technologies16Ultrasound & Echocardiography19811986Nuclear Medicine facilityFourth Generation CT Scan19931994Offer MammographyBone Densitometry19992000Real Time RT-PCR Assays & Flow CytometryAutomated Microbiology Culture20032006Hawkeye Gamma Camera with SPECTCardiac CT & 3.0 Tesla MRI20072009HPV-DNA HC2 test in South IndiaAutomated TB identification & Sensitivity in South India20112012Liquid Based Cytology (Thin Prep) in Andhra Pradesh (AP)IrisiQ200AutomatedUrineAnalyzerwithMicroscopy&Siemen’sAccusonElastography20132017Droplet Digital PCR (ddPCR) & Adv. PET CT in South IndiaUSG-ECHO for Cardiology & Advanced CBCT in South India20193D Mammography with Advanced Technology20192019DNA fragmentation Index test in semenIntegrated modular solution for Immunoassay & Chemistry assays20202020COVID testing by RT-PCR in Telangana & APPhilipsDSAchievawithAmbientExperience20212022‘Walk-in Walk-out Dual source CT’ and ‘BioMatrix3T’Experienced Board and strong management teamExperienced Board and strong management team17One of the leading players in India’s high growth diagnostics marketOne of the leading players in India’s high growth diagnostics market1Integrated diagnostics provider offering one-stop solutionIntegrated diagnostics provider offering one-stop solution2High brand recall driving customer stickinessHigh brand recall driving customer stickiness3Robust technical capabilities and state-of-the-art technologyRobust technical capabilities and state-of-the-art technology45Our Pillars of StrengthIndian Diagnostics Market expected to Grow at a Healthy Trajectory18472684980FY17FY20FY23E+13%CAGRIndian Diagnostics Market43%-44%41%FY23E56% -57%59%57%FY1743%FY20684472980RadiologyPathology+12% CAGR+12% -13%CAGR+14% CAGR+13% -14%CAGR27% -29%FY20190 -195FY23E275 -285+13%CAGRRest of IndiaSouth India71%-73%(INR Bn)FY20Source: CRISIL ReportSegment-wise breakup of Indian Diagnostic MarketOne of the leading players in India’s high growth diagnostics market19Source: CRISIL Report5987FY23EFY20FY17120 -130+14% CAGRGrowthDrivers:•RisingNCDsinthestates•Increasingshareofagedpopulation•Risinghealthawareness•Increasinghealthinsurancepenetration•Conducivegovernmenthealthcareschemes(INR Bn)KarimnagarNizamabadHanamkondaSangareddyHyderabad & SecunderabadKurnoolNandyalNelloreVishakhapatnamWarangalTelangana and Andhra Pradesh Market SizeVijaya’s Core GeographiesDominant Position in Telangana & Andhra PradeshTelangana and Andhra Pradesh (44 -46% of South India)KazipetNCD: Non Communicable diseasesMancherialShamshabadShadnagarRajahmundryIntegrated Diagnostic service provider with extensive network…Flagship Centre= Lab Sample Collection + Basic Radiology + Complete Advanced Radiology (MRI, CT Scan, SPECT & PET CT)Hubs = Lab Samples Collection + Basic Radiology + Advanced Radiology (MRI / CT Scan / SPECT)Spokes = Lab Samples Collection + Basic RadiologyBasic Radiology = ECG / X-ray / USG / Mammography / BMD / TMT / 2D Echo / EEG / ENMG / Endoscopy, etc.20Customer (Walk-in)Home CollectionB2B Hospitals & LabsCustomersSamplesHubs#25Spokes#87#14Reference Lab#1National Reference LabVijaya Diagnostic CentreFlagship Centre#1Sample FlowPatient Flow…offering One-Stop Solutions for Pathology & Radiology21Complete Range of Diagnostic Services under One RoofComprehensive and high quality integrated diagnostic services through our operational networkHigh brand recall driving customer stickiness 2293%FY19FY20FY2190%92%1,2281,2141,4311,276454475631562FY19FY20FY21Revenue per footfallEBITDA per footfallB2C RevenueOperational MetricsHigher brand recallHigh share of walk-in customersSticky individual customerCustomer Centric ApproachQuality Diagnostic Services“One of the Best Healthcare Brands 2021”by The Economic Times in 2021“For excellence in Quality and Accuracy” under the category Leading Diagnostics company with Excellence in Quality and Safety at the Diagnostics Leadership Summit in 2021(INR)FY2294%FY22Robust Technical Capabilities with State-of-the-art IT Infrastructure•Longstandingrelationshipwithmedicaltechnologyvendors•Attheforefrontofintroducingnewtestsbyadoptingthelatestmedicaltechnologies•AmongthefirstdiagnosticserviceproviderinSouthIndiatoofferPET-CTscanin200820CT Machines6PET CT / Gamma machinesRadiologists, Lab Doctors & Physicians200+MRI Machines2123Key SuppliersNABL Accreditations11NABH Accreditations5Advanced Software to Manage Clinical DataAdvance Laboratory Information Management System (LIMS)Fully Integrated Radiology Information Systems (RIS) and Picture Archive and Communication Systems (PACS)Front end IT infrastructure enabling…StandardizationacrossouroperationsReduceincidenceoferrorsduetoLowHumanInterventionMonitorTechnicalOperationsCloselytrackkeyperformancemetricsandmaintaintheTurn-AroundTime(TAT)ProvideUniformExperiencetocustomersfrombookingappointmentstoaccessingreportsonlineExperienced Board of DirectorsDr. S Surendranath Reddy -Executive ChairmanFounderofVijayawith40+yearsofexperienceinbuildingVijayaasSouthIndia’slargestintegrateddiagnosticchainHoldsBachelor’sdegreeinMedicineandProvisionaldegreeofDoctorofMedicineinRadiologyS Geeta Reddy -Non-Executive Director EnrolledasadvocatewithAndhraPradeshHighCourtin1986HoldsaBachelor’sdegreeinLawfromOsmaniaUniversitySunil Chandra Kondapally -Executive DirectorBeenwithVijayasince2002and17+yearsofexperienceinhealthcareHoldsBachelor’sdegreeinElectricalEngineeringfromFloridaStateUniversityDr. D NageshwarReddy -Non-executive, Independent DirectorChairmanofAsianInstituteofGastroenterology(AIG),HyderabadAwardedPadmaShriandPadmaBhushanbyGovernmentofIndiaD.MinGastroenterologyfromPGIMERChandigarhShekhar Prasad Singh -Non-executive, Independent DirectorEx-ChiefSecretarytoGovernmentofTelanganaRetiredIASofficerof1983batchSatyanaryanaMurthy Chavali-Non-executive, Independent DirectorEx-CEOofAurigeneDiscoveryTechnologiesLtd.HoldsBTechfromIIT,MadrasandMBAfromIIM,BangaloreDr. Manjula Anagani-Non-executive, Independent DirectorClinicalDirectorandHeadofDepartmentofcentreofwomenandchildcareatCarehospitalsAwardedPadmaShribyGovernmentofIndiaMDinObstetricsandGynecologyfromN.T.R.UniversityofHealthSciences24Strong Management Team25Dr. S. SurendranathReddyExecutive ChairmanMr. Narasimha Raju K.AChief Financial OfficerMs. Suprita ReddyChief Executive OfficerMr. Sunil Chandra KondapallyExecutive DirectorMs. Anusha KanumuruCompany Secretary & Compliance Officer40+yearsofexperienceinbuildingVijayaasSouthIndia’slargestintegrateddiagnosticchainHoldsBachelor’sdegreeinMedicineandProvisionaldegreeofDoctorofMedicineinRadiologyHeisalifememberoftheIndianRadiologicalandImagingAssociation.WithVijayasinceincorporationandexperiencedinoperations,qualityaccreditation,finance,marketingandnetworkexpansiondepartments17+Yearsofexperienceinhealthcareindustry&foundedTrikonaPharmaceuticalsPvt.Ltd.(2016)andQPSBioserveIndiaPvt.Ltd.(2004)Holdsbachelor’sdegreeinelectricalengineeringfromFloridaStateUniversityWithVijayasince2003andheadsoverallstrategy,clinicalexcellence,operationsandexpansionofthecompanyAwardedWomenLeadershipAwardinHealthcarebyABPin2019HoldsbachelorsdegreeincommercefromOsmaniaUniversityAssociatedwithVijayafromJune2017toNov2020andrejoinedinMarch202114+yearsofexperienceinaudit,financialreporting,regulatorycomplianceandaccountingadvisoryPreviouslyworkedwithSRBaltliboi&Co.,NSLRenewablePowerPvt.Ltd.etcHoldsbachelor’sdegreeofcommercefromOsmaniaUniversityandmemberoftheInstituteofCharteredAccountantsofIndia12+yearsofexperienceinhandlingworksrelatingtopublicissue(s),privateplacement(s),merger(s),foreigninvestment,listingformalitieswiththeStockExchanges,CompanyLaw,FEMAandStockExchangeCompliancesincludingregulatoryapprovalsAssociatememberofICSIandholdsBachelor'sdegreeinCommerceandCorporateAffairsPreviouslyworkedwithAurobindoRealty,IVRCLLtdetcAwards & Accolades26Pride of India Brands Award 2022One of the Best Healthcare Brands 2021Indo Global Award for Healthcare ExcellenceCompany ofthe Year -HealthcareHealthcare Leadership Awards 2022India’s Greatest Brands 2020-21 Pride of NationIndia’s Greatest Brands 2020-21 Pride of NationLeading Diagnostics with Excellence in Quality & SafetyMost Trusted and Best Quality Diagnostic services in IndiaHealthcare Entrepreneur of the Year –Dr. Surendra Reddy2021Presented byThe Economic Times 2019Presented byIndo-Arab LeadersSummit & Awards2021 PresentedbyUnited Research Services2021 PresentedbyDiagnostic Leadership Summit2021 PresentedbyDiagnostic Leadership Summit2021 PresentedbyUnited Research Services2020Presented byTimes Healthcare Achievers2019Presented bySix SigmaHealthcare2019Presented byUnited Research Services2019Presented bySix Sigma HealthcareBest Diagnostic Centre of the YearLeading Chain of Diagnostics & ImagingBest Diagnostic Service Provider of the YearMost TrustedDiagnostic Centre of the YearTelanganaHealthcare Leadership Awards2019Presented byTimes Healthcare Achievers2019Presented byIndian Medical Association, Telangana state and Messe India2018Presented byTelangana Government2021 PresentedbyIndian Economic Development & Research Association2021 PresentedbyTV9 Network and SAPBest Healthcare Brands 2022Leading Diagnostic Chain of the YearFastest Growing Brands (Pride of the Nation)2022 Presented byThe Economic Times 2022 PresentedbyeHealth Magazine2022 PresentedbyThe Best of South AwardsShareholding Pattern as of 30thSep 2022DIIsOthers55.0%15.8%23.9%5.3%Promoter & Promoter group27Marquee Institutional Investors WasatchAdvisorsAxis Mutual FundNippon Life IndiaAsset ManagementAberdeen Standard InvestmentsFidelity Group Abu Dhabi Investment AuthorityDSP Mutual FundAditya Birla Sun Life Asset ManagementAs on 30thSeptember 2022DII’s: Mutual Funds, AIF’s and QIB’sOthers: Retail, Bodies Corporate and others FII’sStrategy Going Forward29KarimnagarNizamabadHanamkondaSangareddyHyderabad & SecunderabadKurnoolNandyalNelloreVishakhapatnamWarangalConsolidate Leading PositionGiven our significant presence and operational experience in Telangana and Andhra Pradesh, we intend to deepen our penetration and increase customer base by Enhancing laboratory capacity and test menu by adding latest technologiesOffering value added servicesPhysician engagements (by conducting continuous medical education programs)Leveraging Existing PresenceGiven under-penetration of diagnostic market, we will continue to focus onOpening additional diagnostic centresthrough owned & franchisee modelExpanding network through setting up spokes and hubs in existing catchment areasAdding reference laboratories in our existing core geographiesKazipetDeepen Footprint in our Core Markets -Telangana & Andhra PradeshMancherialShamshabadShadnagarRajahmundryExpand in Adjacent Geographies & East India30East India StrategyExpand presence in East India given growing demandReplicate our successful hub and spokes model in East IndiaEstablished a hub in Kolkata and plan is to set up additional diagnostic centres around itHence, Kolkata to be our focus area for medium to long term growthExpand in concentric circles given our hub and spoke modelEstablish presence in adjacent geographies Identified key cities and towns which are underserved and our brand is well-regardedWider geographic reach will expand our customer base leading to better profitability by leveraging our infrastructureSouth India StrategyAP: Andhra Pradesh86252HyderabadRest of Telanganaand APOthersNetwork (FY22)Continued Focus on Providing Customer Centric Services and OfferingsSource: CRISIL Report31Preventive and Wellness Testing to Boost Demand for DiagnosticsFY20EFY23PWellness & Preventive9% -10%Rest of the market90%Wellness & Preventive11%Rest of the market89%IncreasingchronicandlifestylediseasesCorporatetie-upsIncreasingdisposableincomeIncreasingserviceofferingsKey DriversIncreasediagnosticservicesbyofferingadditionalpreventiveandwellnessservicesthroughadoptionofnewcutting-edgediagnostictestingtechnologyProvidinghomecollectionservicesandpoint-of-contacttestingtocomplementwalk-inExpandspecialtytests,diseasespecificprofilesandprovidecustomizedpackagesGrowourcorporatecustomerbasebycateringtotheirneedsExpansionofchronicdiseasemanagementandwellnessprogramsOur StrategyIndustry Size61-68FY20FY23101-108CAGR: ~20%Financial & Operational HighlightsRobust Operational MetricsDiagnostic Centre (Nos)Footfalls (Mn)Tests Performed (Mn)Test per Footfall (Nos)Revenue per Test (INR)Revenue per Footfall(INR)3361738095FY19FY20FY21FY222.382.792.633.62FY19FY20FY21FY226.997.917.099.32FY19FY20FY21FY222.932.832.692.57FY19FY20FY21FY22419428531496FY19FY20FY21FY221,2281,2141,4311,276FY19FY20FY21FY22Impact of COVID-19Consistent Financial PerformanceCAGR:16%RevenueEBIDTAPATCAGR:24%CAGR:34%EBIDTA Margin (%)710 bpsPAT Margin (%)800 bps(INR Mn)342,9263,3883,7674,624FY19FY20FY21FY221,0811,3261,6602,037FY19FY20FY21FY2237.0%39.1%44.1%44.1%FY19FY20FY21FY2215.7%18.5%22.4%23.7%FY19FY20FY21FY224596258451,097FY19FY20FY21FY22Sustainable Cash Generation & Increasing Return RatiosCFO / EBIDTA (%)RoCEPre-Cash (%)RoE(%)Cash & Cash EquivalentsCFO = Cash flow from Operations(INR Mn)35ROCE (Pre-cash): PBIT ex Other income / (Total Assets –Cash –Current Liabilities)1,2151,7292,2772,467FY19FY20FY21FY2230%33%43%38%FY19FY20FY21FY2284%80%78%77%FY19FY20FY21FY2222%23%23%23%FY19FY20FY21FY22AnnexureConsolidated Profit & Loss AccountParticularsFY22FY21FY20FY19Revenue from operations4,6243,7673,3882,926Cost of materials consumed715571439405Employee benefits expense707574624539Other expenses1,165962999901EBITDA2,0371,6601,3261,081EBITDA %44.1%44.1%39.1%37.0%Other income128118154104Depreciation and amortization expense527505492396EBIT1,6381,274988789Finance costs165152154135Profit before Tax1,4741,121834653Tax expenses367270209190Profit after Tax before Minority Interest1,107851625463MinorityInterest10604Profit afterTax1,097845625459PAT %23.7%22.4%18.5%15.7%EPS –Basic(INR)10.768.286.134.50(INR Mn)37Consolidated Balance SheetAssetsMar-22Mar-21Mar-20Mar-19NON-CURRENT ASSETS4,4363,0222,9592,689Property, plant and equipment1,9661,3581,3981,437Capital work-in-progress341829327Goodwill53535369Other intangible assets146107Right of use asset1,6721,2601,2541,079Intangible assets under development1124-Financial assets-Investments0000-Other financial assets751225543Deferred tax assets89611612Income tax assets2698Other assets22361677CURRENT ASSETS2,6992,3881,8651,374Inventories43262822Financial assets-Investments542276547688-Trade receivables98648091-Cash and cash equivalents1106755696-Bank balances other than Cash and cash equivalents1,8131,876626430-Loans0014-Other financial assets5152526Other current assets41272217TOTAL ASSETS7,1355,4094,8244,063EQUITY AND LIABILITIESMar-22Mar-21Mar-20Mar-19EQUITY4,6953,5922,7412,069Equity share capital102454545Instruments entirely equity in nature---24Other equity4,5933,5472,6962,000NON-CURRENT LIABILITIES1,7781,3771,4941,422Financial liabilities-Borrowings033221315-Lease liabilities1,7031,2651,1961,034-Other financial liabilities02919Provisions74776753Other liabilities1111CURRENT LIABILITIES661440589572Financial liabilities-Borrowings6121320-Lease liabilities1261018873-Trade payables216222217218-Other financial liabilities24861224204Income tax liabilities9161515Provisions2171111Other liabilities35202131TOTAL EQUITY AND LIABILITIES7,1355,4094,8244,063(INR Mn)38Consolidated Cash Flow StatementParticularsMar-22Mar-21Mar-20Mar-19Cash Flow from Operating ActivitiesProfit before Tax1,4741,121834653Adjustment for Non-Operating Items572534492431Operating Profit before Working Capital Changes2,0461,6551,3261,084Changes in Working Capital-67-46-328Cash Generated from Operations1,9751,6091,2941,092Less: Direct Taxes paid-399-312-233-187Net Cash from Operating Activities1,5801,2971,061905Purchase and constructionof property, plant and building (net)-1,223-312-375-591Investments (net)-127-1,03311-314Others12047576Cash Flow from Investing Activities-1,226-1,298-306-898Cash Flow from Financing Activities-306-488-295-72Net increase/ (decrease) in Cash & Cash equivalent44-489460-65Cash & Cash Equivalents at the beginning of the period6755696161Cash & Cash equivalents at the end of the period1106755696(INR Mn)39ParticularsMar-22Mar-21Mar-20Mar-19Investments*543335547688Cash and cash equivalents1106755696Bank balances other than Cash and cash equivalents1,8131,876626430Total2,4672,2771,7291,215Cash and Cash Equivalents *Current investments + investments with maturity more than 12 months (part of other non-current financial assets)Mr. Siva Rama Raju –Head of Strategy +91 90597 00749 / +91 99485 95555sivaramaraju.v@vijayadiagnostic.inir@vijayadiagnostic.inwww.vijayadiagnostic.comVijaya Diagnostic Centre Limited (VDCL)CompanyInvestor Relations Advisors#6-3-883/F, Ground Floor, FPAI Building, Punjagutta, Officers Colony, Near Topaz Building, Hyderabad-500082, Telangana, India.THANK YOUMr. Anoop Poojari /Mr. Devrishi SinghTel: +91 98330 90434 / +91 98205 30918anoop@cdr-india.comdevrishi@cdr-india.comCitigateDewe Rogerson (CDR India)